Risk factors for early, cumulative, and fatal infections after heart transplantation: a multiinstitutional study

J Heart Lung Transplant. 1996 Apr;15(4):329-41.

Abstract

Background and methods: By multivariable analysis, risk factors were identified for initial infection of any type, cumulative infections during the first 6 months and fatal infection among 2210 heart transplant recipients at 30 institutions.

Results and conclusions: Of the 1218 infections in 695 patients, bacterial infections were most frequent (47%), followed by viral (42%), fungal (8%), and protozoal (4%). Risk factors for earlier infection included older recipient age (p < 0.0001), ventilator support at time of transplant (p < 0.0001), ventricular assist device at time of transplant (p = 0.02), OKT3 induction therapy (p < 0.0001), donor black race (p = 0.0007), and positive donor cytomegalovirus serology (for cytomegalovirus infection) (p = 0.0007). Cumulative infections during the first 6 months were increased by older recipient age (p < 0.0001), ventilator support at transplant (p = 0.0004), ventricular assist at transplant (p = 0.009), Black donor (p = 0.03), female donor (p = 0.03), and OKT3 induction therapy (p = 0.005). The actuarial freedom from fatal infection was 96% at 1 year and 95% at 3 years. Risk factors for death from infection included very old (p = 0.002) and very young recipients (p = 0.004), ventilator support at time of transplant (p = 0.004), older donor (p < 0.0001), and longer donor ischemic time (p = 0.02). The risk of death from infection within the first 3 months exceeded 20% among older recipients (> 55 years) on ventilator support at time of transplantation who received an older (> 50 years) donor heart.

Publication types

  • Multicenter Study

MeSH terms

  • Actuarial Analysis
  • Age Factors
  • Bacterial Infections / epidemiology*
  • Black or African American
  • Female
  • Heart Transplantation*
  • Heart-Assist Devices
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Muromonab-CD3 / therapeutic use
  • Mycoses / epidemiology*
  • Postoperative Complications / epidemiology*
  • Protozoan Infections / epidemiology*
  • Respiration, Artificial
  • Risk Factors
  • Sex Factors
  • Time Factors
  • Tissue Donors
  • Virus Diseases / epidemiology*

Substances

  • Immunosuppressive Agents
  • Muromonab-CD3